Compare TRT & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRT | KYNB |
|---|---|---|
| Founded | 1958 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 31.9M |
| IPO Year | 1995 | N/A |
| Metric | TRT | KYNB |
|---|---|---|
| Price | $5.80 | $6.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 60.8K | 30.7K |
| Earning Date | 05-12-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $32,462,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $305.50 | ★ $0.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.42 | $6.54 |
| 52 Week High | $14.78 | $9.58 |
| Indicator | TRT | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 39.61 |
| Support Level | $5.01 | N/A |
| Resistance Level | $6.48 | $7.58 |
| Average True Range (ATR) | 0.51 | 0.37 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 44.03 | 23.89 |
Trio-Tech International operates in the semiconductor industry, providing manufacturing, testing, and distribution services for semiconductor test equipment and electronic components. It has two main segments: Semiconductor Back-end Solutions (SBS) and Industrial Electronics (IE). The SBS segment, which generates the majority of the Company's revenue, focuses on manufacturing equipment for semiconductor back-end processes, offering testing services, and distributing burn-in test related equipment. The IE segment manufactures equipment for other industries and distributes electronic products outside the semiconductor sector. The Company operates in the United States, Singapore, Malaysia, Thailand, and China, serving customers across multiple regions.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.